Paraoxonase-1 (PON-1), an enzyme with antioxidant properties, has been advocated as potential pathogenic player for many diseases. In particular, a decline in serum PON-1 activities (arylesterase and paraoxonase), has been associated with several neurological diseases, especially dementia. In this study, we aimed to: (1) measure the PON-1 activities in patients with mild cognitive impairment (MCI, n=232), Alzheimer’s disease (LOAD, n=175), vascular dementia (VAD, n=65) and mixed dementia (MD, n=88); (2) explore the association between PON-1 measured in serum and cerebrospinal fluid (CSF) and multiple sclerosis (MS, n=104). Serum arylesterase, but not paraoxonase, activity was lower in patients with MCI, VAD, LOAD, MD and MS than healthy controls. Notably, the most pronounced decline in this activity was shown by MD (−18%, p<0.01) and MS (−23%, p<0.001). Only arylesterase activity was detectable in the CSF and its levels did not differ between MS and neurological control groups. Our data suggest that a depressed arylesterase activity could be a common denominator of different neurological diseases which appear to be all characterized by an altered systemic redox balance.
Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases
TRENTINI, Alessandro;ROMANI, Arianna;CASTELLAZZI, Massimiliano;VALACCHI, Giuseppe;MANFRINATO, Maria Cristina;BELLINI, Tiziana;BONACCORSI, Gloria;FAINARDI, Enrico;CAVICCHIO, Carlotta;PASSARO, Angelina;ZULIANI, Giovanni;CERVELLATI, Carlo
2016
Abstract
Paraoxonase-1 (PON-1), an enzyme with antioxidant properties, has been advocated as potential pathogenic player for many diseases. In particular, a decline in serum PON-1 activities (arylesterase and paraoxonase), has been associated with several neurological diseases, especially dementia. In this study, we aimed to: (1) measure the PON-1 activities in patients with mild cognitive impairment (MCI, n=232), Alzheimer’s disease (LOAD, n=175), vascular dementia (VAD, n=65) and mixed dementia (MD, n=88); (2) explore the association between PON-1 measured in serum and cerebrospinal fluid (CSF) and multiple sclerosis (MS, n=104). Serum arylesterase, but not paraoxonase, activity was lower in patients with MCI, VAD, LOAD, MD and MS than healthy controls. Notably, the most pronounced decline in this activity was shown by MD (−18%, p<0.01) and MS (−23%, p<0.001). Only arylesterase activity was detectable in the CSF and its levels did not differ between MS and neurological control groups. Our data suggest that a depressed arylesterase activity could be a common denominator of different neurological diseases which appear to be all characterized by an altered systemic redox balance.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
